Relieva is redefining therapeutic innovation through the world’s first proprietary cannabis and hemp pre-roll blend engineered for targeted pain relief. Leveraging advanced cannabinoid and terpene research, Relieva integrates scientific precision, sustainable production, and blockchain-enabled IP tokenization to establish a new benchmark in functional medicine innovation and therapeutic transparency.

We are developing a new gene therapy to help our canine companions stay stronger, move more comfortably, and enjoy healthier lives as they age. By supporting muscle growth, easing pain, and calming inflammation linked to arthritis, our follistatin therapy aims to improve everyday mobility and overall wellbeing.

Our Moon Drops for Skin Longevity serum optimizes the clinically proven Ferulic Acid + Vitamin C + Vitamin E winning combo using safe, high-purity actives. The combination of our Sun Drops UV filter enhances anti-aging skin protection and restoration with active development powered by inclusive decentralized trial protocols.

We are developing a new RNA-based treatment to target a key longevity gene, aiming to stop the tissue damage behind chronic back pain and offer a safer, longer-lasting solution.

Nootropics DAO is building the world's most effective global infrastructure for decentralized research, discovery, and commercialization of powerful solutions for human cognitive enhancement. By creating an open-science ecosystem that aligns professional researchers, citizen-scientists, and biohackers to govern a community-directed research and development pipeline with hyper-efficient feedback loops, Nootropics DAO is operating to become the dominant force in the rapidly growing nootropics industry.

The galectin-3 Inhibitors project tests a small molecule under development for peripheral indications for treating neuroinflammation in an Alzheimer’s mouse model. By blocking galectin-3, it aims to reduce brain inflammation, with potential in other neurodegenerative diseases. Galectin-3 is involved in neuroinflammation, thereby the inhibitor has a potential to be used in multiple neurodegenerative diseases.

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.

D1ckGPT is a BioAgent that makes your D1ck stronger by assessing its age and guiding you on how to reverse it. Trained on 600+ clinician-curated studies with its own Decentralized Knowledge Graph, every interaction enhances D1ckGPT's intelligence, revolutionizing traditional care and accelerating science and drug discovery in men's health. Whether it’s optimizing testosterone, boosting cognitive edge, or getting smarter about longevity.

BiomeAI is a cutting-edge health assistant powered by over 1,000 rigorously curated scientific studies on microbiome science and real-world experiments, designed to help people make smarter, personalized health choices with trustworthy data as its foundation. Built and advised by a team of top experts in gut health and AI, BiomeAI blends deep scientific credibility with participatory governance model to let users test, learn, and figure out what works for them. Every experiment and health insight feeds into a transparent, collective knowledge base that grows with you and the active community. Holding $BIOMEAI grants exclusive first access to the most validated N=10 trial protocols and the next big gut health breakthrough. Top yappers and traders gain a winning chance to earn free microbiome tests by completing community missions, turning engagement into tangible health value.

eDMT Commons enables shared governance over multiple R&D efforts into how the brain regulates its own DMT. This Commons IPT coordinates funding across diverse approaches, accelerating discovery while ensuring knowledge remains community-governed. Token holders benefit from any project funded by or joining the consortium. The flagship project seeks to uncover how endogenous DMT is regulated in the mammalian brain by isolating and sequencing enzymes that act as an “off switch” for DMT production. This work could provide the foundation for protocols to induce sustained DMT states through internal pathways (“endo-DMTx”), opening new therapeutic avenues for neuroprotection, learning, and mood regulation.

Aubrai is the world’s first decentralized scientific agent with knowledge stemming from thousands of private lab notes, internal chats and unpublished insights from the lab of Dr. Aubrey de Grey and the collective intelligence of the global longevity community. Co-developed by VitaDAO and BIO, the first BioAgent is designed to fight the greatest killer of all time: Aging. As an onchain AI co-scientist, Aubrai can generate and validate hypotheses, design wet-lab experiments and encrypt data when asked, enriching research outputs while protecting trade secrets. At the heart of Aubrai's mission lies the Robust Mouse Rejuvenation (RMR2) project – Aubrey's ambitious study to double the remaining lifespan of middle‑aged mice. If successful, it could be aging's "AlphaFold moment": a proof that multi‑target rejuvenation works and is worth scaling.